請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36176
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭明良 | |
dc.contributor.author | Chia-Hung Chou | en |
dc.contributor.author | 周佳宏 | zh_TW |
dc.date.accessioned | 2021-06-13T07:53:03Z | - |
dc.date.available | 2006-08-12 | |
dc.date.copyright | 2005-08-12 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-25 | |
dc.identifier.citation | Chapter1
References 1. Mills, G.B., May, C., McGill, M., Roifman, C.M. and Mellors, A. (1988) A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res, 48, 1066-71. 2. Mills, G.B., May, C., Hill, M., Campbell, S., Shaw, P. and Marks, A. (1990) Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest, 86, 851-5. 3. Xu, Y., Gaudette, D.C., Boynton, J.D., Frankel, A., Fang, X.J., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A. and et al. (1995) Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res, 1, 1223-32. 4. Westermann, A.M., Havik, E., Postma, F.R., Beijnen, J.H., Dalesio, O., Moolenaar, W.H. and Rodenhuis, S. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol, 9, 437-42. 5. Pages, C., Simon, M.F., Valet, P. and Saulnier-Blache, J.S. (2001) Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat, 64, 1-10. 6. Shen, Z., Belinson, J., Morton, R.E. and Xu, Y. (1998) Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol, 71, 364-8. 7. Contos, J.J., Ishii, I. and Chun, J. (2000) Lysophosphatidic acid receptors. Mol Pharmacol, 58, 1188-96. 8. Hu, Y.L., Albanese, C., Pestell, R.G. and Jaffe, R.B. (2003) Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst, 95, 733-40. 9. Frankel, A. and Mills, G.B. (1996) Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res, 2, 1307-13. 10. Hu, Y.L., Tee, M.K., Goetzl, E.J., Auersperg, N., Mills, G.B., Ferrara, N. and Jaffe, R.B. (2001) Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst, 93, 762-8. 11. Schwartz, B.M., Hong, G., Morrison, B.H., Wu, W., Baudhuin, L.M., Xiao, Y.J., Mok, S.C. and Xu, Y. (2001) Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol, 81, 291-300. 12. Fishman, D.A., Liu, Y., Ellerbroek, S.M. and Stack, M.S. (2001) Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res, 61, 3194-9. 13. Pustilnik, T.B., Estrella, V., Wiener, J.R., Mao, M., Eder, A., Watt, M.A., Bast, R.C., Jr. and Mills, G.B. (1999) Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res, 5, 3704-10. 14. Hirano, T., Nakajima, K. and Hibi, M. (1997) Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev, 8, 241-52. 15. Watson, J.M., Sensintaffar, J.L., Berek, J.S. and Martinez-Maza, O. (1990) Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res, 50, 6959-65. 16. Asschert, J.G., Vellenga, E., Ruiters, M.H. and de Vries, E.G. (1999) Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer, 82, 244-9. 17. Plante, M., Rubin, S.C., Wong, G.Y., Federici, M.G., Finstad, C.L. and Gastl, G.A. (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 73, 1882-8. 18. van der Zee, A.G., de Cuyper, E.M., Limburg, P.C., de Bruijn, H.W., Hollema, H., Bijzet, J., Krans, M. and de Vries, E.G. (1995) Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer, 75, 1004-9. 19. Penson, R.T., Kronish, K., Duan, Z., Feller, A.J., Stark, P., Cook, S.E., Duska, L.R., Fuller, A.F., Goodman, A.K., Nikrui, N., MacNeill, K.M., Matulonis, U.A., Preffer, F.I. and Seiden, M.V. (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer, 10, 33-41. 20. Ishioka, S., van Haaften-Day, C., Sagae, S., Kudo, R. and Hacker, N.F. (1999) Interleukin-6 (IL-6) does not change the expression of Bcl-2 protein in the prevention of cisplatin-induced apoptosis in ovarian cancer cell lines. J Obstet Gynaecol Res, 25, 23-7. 21. Obata, N.H., Tamakoshi, K., Shibata, K., Kikkawa, F. and Tomoda, Y. (1997) Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res, 17, 337-42. 22. Fang, X., Yu, S., Bast, R.C., Liu, S., Xu, H.J., Hu, S.X., LaPushin, R., Claret, F.X., Aggarwal, B.B., Lu, Y. and Mills, G.B. (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem, 279, 9653-61. 23. Qian, L., Xu, Y., Hasegawa, Y., Aoki, J., Mills, G.B. and Prestwich, G.D. (2003) Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem, 46, 5575-8. 24. Zhu, Y., Maric, J., Nilsson, M., Brannstrom, M., Janson, P.O. and Sundfeldt, K. (2004) Formation and Barrier Function of Tight Junctions in Human Ovarian Surface Epithelium. Biol Reprod. 25. Deng, H., Chu, J.T., Rettig, M.B., Martinez-Maza, O. and Sun, R. (2002) Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. Blood, 100, 1919-21. 26. Mills, G.B. and Moolenaar, W.H. (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer, 3, 582-91. 27. Frankel, A., Rosen, K., Filmus, J. and Kerbel, R.S. (2001) Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res, 61, 4837-41. 28. Xiao, Y.J., Schwartz, B., Washington, M., Kennedy, A., Webster, K., Belinson, J. and Xu, Y. (2001) Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem, 290, 302-13. 29. Xu, Y., Shen, Z., Wiper, D.W., Wu, M., Morton, R.E., Elson, P., Kennedy, A.W., Belinson, J., Markman, M. and Casey, G. (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Jama, 280, 719-23. 30. Xu, Y., Fang, X.J., Casey, G. and Mills, G.B. (1995) Lysophospholipids activate ovarian and breast cancer cells. Biochem J, 309 ( Pt 3), 933-40. 31. Goetzl, E.J., Dolezalova, H., Kong, Y., Hu, Y.L., Jaffe, R.B., Kalli, K.R. and Conover, C.A. (1999) Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res, 59, 5370-5. 32. Fang, X., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R.B., Wiener, J.R., Erickson, J.R. and Mills, G.B. (2000) Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci, 905, 188-208. 33. Furui, T., LaPushin, R., Mao, M., Khan, H., Watt, S.R., Watt, M.A., Lu, Y., Fang, X., Tsutsui, S., Siddik, Z.H., Bast, R.C. and Mills, G.B. (1999) Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res, 5, 4308-18. 34. van Corven, E.J., Hordijk, P.L., Medema, R.H., Bos, J.L. and Moolenaar, W.H. (1993) Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proc Natl Acad Sci U S A, 90, 1257-61. 35. van Dijk, M.C., Postma, F., Hilkmann, H., Jalink, K., van Blitterswijk, W.J. and Moolenaar, W.H. (1998) Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways. Curr Biol, 8, 386-92. 36. Kranenburg, O. and Moolenaar, W.H. (2001) Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene, 20, 1540-6. 37. van Corven, E.J., Groenink, A., Jalink, K., Eichholtz, T. and Moolenaar, W.H. (1989) Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell, 59, 45-54. 38. Fang, X., Yu, S., LaPushin, R., Lu, Y., Furui, T., Penn, L.Z., Stokoe, D., Erickson, J.R., Bast, R.C., Jr. and Mills, G.B. (2000) Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J, 352 Pt 1, 135-43. 39. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K. and Kasuga, M. (1999) PI 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. Embo J, 18, 386-95. 40. Philp, A.J., Campbell, I.G., Leet, C., Vincan, E., Rockman, S.P., Whitehead, R.H., Thomas, R.J. and Phillips, W.A. (2001) The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61, 7426-9. 41. Hu, L., Hofmann, J., Lu, Y., Mills, G.B. and Jaffe, R.B. (2002) Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res, 62, 1087-92. 42. Sheng, H., Shao, J. and Dubois, R.N. (2001) K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res, 61, 2670-5. 43. Monick, M.M., Robeff, P.K., Butler, N.S., Flaherty, D.M., Carter, A.B., Peterson, M.W. and Hunninghake, G.W. (2002) Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem, 277, 32992-3000. 44. Romashkova, J.A. and Makarov, S.S. (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401, 86-90. 45. Chandrasekar, B., Bysani, S. and Mummidi, S. (2004) CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem, 279, 3188-96. 46. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. (2001) Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res. 7:2941-8. 47. Syed V, Ulinski G, Mok SC, Ho SM. (2002) Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells.J Natl Cancer Inst. 94 :617-29. Chapter2 References 1. Mills, G.B., May, C., McGill, M., Roifman, C.M. and Mellors, A. (1988) A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res, 48, 1066-71. 2. Mills, G.B., May, C., Hill, M., Campbell, S., Shaw, P. and Marks, A. (1990) Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest, 86, 851-5. 3. Xu, Y., Gaudette, D.C., Boynton, J.D., Frankel, A., Fang, X.J., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A. and et al. (1995) Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res, 1, 1223-32. 4. Westermann, A.M., Havik, E., Postma, F.R., Beijnen, J.H., Dalesio, O., Moolenaar, W.H. and Rodenhuis, S. (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol, 9, 437-42. 5. Pages, C., Simon, M.F., Valet, P. and Saulnier-Blache, J.S. (2001) Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat, 64, 1-10. 6. Shen, Z., Belinson, J., Morton, R.E. and Xu, Y. (1998) Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol, 71, 364-8. 7. Contos, J.J., Ishii, I. and Chun, J. (2000) Lysophosphatidic acid receptors. Mol Pharmacol, 58, 1188-96. 8. Hu, Y.L., Albanese, C., Pestell, R.G. and Jaffe, R.B. (2003) Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst, 95, 733-40. 9. Frankel, A. and Mills, G.B. (1996) Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res, 2, 1307-13. 10. Hu, Y.L., Tee, M.K., Goetzl, E.J., Auersperg, N., Mills, G.B., Ferrara, N. and Jaffe, R.B. (2001) Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst, 93, 762-8. 11. Schwartz, B.M., Hong, G., Morrison, B.H., Wu, W., Baudhuin, L.M., Xiao, Y.J., Mok, S.C. and Xu, Y. (2001) Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol, 81, 291-300. 12. Penson, R.T., Kronish, K., Duan, Z., Feller, A.J., Stark, P., Cook, S.E., Duska, L.R., Fuller, A.F., Goodman, A.K., Nikrui, N., MacNeill, K.M., Matulonis, U.A., Preffer, F.I. and Seiden, M.V. (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer, 10, 33-41. 13. Ishioka, S., van Haaften-Day, C., Sagae, S., Kudo, R. and Hacker, N.F. (1999) Interleukin-6 (IL-6) does not change the expression of Bcl-2 protein in the prevention of cisplatin-induced apoptosis in ovarian cancer cell lines. J Obstet Gynaecol Res, 25, 23-7. 14. Obata, N.H., Tamakoshi, K., Shibata, K., Kikkawa, F. and Tomoda, Y. (1997) Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res, 17, 337-42. 15. Fishman, D.A., Liu, Y., Ellerbroek, S.M. and Stack, M.S. (2001) Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res, 61, 3194-9. 16. Pustilnik, T.B., Estrella, V., Wiener, J.R., Mao, M., Eder, A., Watt, M.A., Bast, R.C., Jr. and Mills, G.B. (1999) Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res, 5, 3704-10. 17. Bell DA.( 2005) Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol,18 Suppl 2:S61-79. Review. 18 Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM.( 1994) YC-1, a novel activator of platelet guanylate cyclase. Blood. , 84(12):4226-33. 19 Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer.Cancer Lett. 2004 Apr 15;207(1):1-7. Review. 20 Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW. (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol. 2001 ,61(8):947-54. 21 Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW(2003).YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst, 95(7):516-25. 22 Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM.(2005) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Haemost. 93(5):940-8. 23 Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM.(2005) YC-1 [3-(5'-Hydroxymethyl-2'-Furyl)-1 -Benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors In Vitro and Angiogenesis In Vivo Models. J Pharmacol Exp Ther.; [Epub ahead of print] 24. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS.(1996) Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer.;67(5):695-701. 25 Massa EM, Farias RN. (1983)Effect of auto-oxidized phospholipids on oxidative enzyme assays based on tetrazolium salt reduction. Biochim Biophys Acta., 746(3):209-15. 26 Klebe RJ. (1975) The binding of the mucoprotein from gastric mucus to cells in tissue culture and the inhibition of cell adhesion. J Cell Sci. 86(2 Pt 1):231-6. 27 Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB.(200) Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000, 6(6):2482-91. 28 Frisch SM, Ruoslahti E.(1997) Integrins and anoikis. Curr Opin Cell Biol.;9(5):701-6. Review. 29 Flamme I, von Reutern M, Drexler HC, Syed-Ali S, Risau W.(1995) Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol;171(2):399-414. 30 Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998, 17(2):155-61. Review. 31 Xu, Y., Shen, Z., Wiper, D.W., Wu, M., Morton, R.E., Elson, P., Kennedy, A.W., Belinson, J., Markman, M. and Casey, G. (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Jama, 280, 719-23. 32 Xu, Y., Fang, X.J., Casey, G. and Mills, G.B. (1995) Lysophospholipids activate ovarian and breast cancer cells. Biochem J, 309 ( Pt 3), 933-40. 33 Markowska J, Szala S.(2004) Inhibitors of angiogenesis in therapy of ovarian cancers. Eur J Gynaecol Oncol ;25(5):562-7. Review. 34 Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, Kohno T, Konno R, Ohwada M, Suzuki M. (2005) Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer. 20; 114(2):224-9. 35 Subramanian IV, Ghebre R, Ramakrishnan S.(2005) Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther ;12(1):30-8. 36 Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K.(1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res ;53(11):2566-70. 37 Kong H, Jin Z, Yao M.(2002) Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaniously in nude mice Zhonghua Fu Chan Ke Za Zhi. ;37(9):556-8. Chinese. 38 Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K. (2003) Interleukin-10- mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res.;63(16):5091-4. 39 Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel-D, Khalifa A.(2004) Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem.;37(5):363-9. 40 English D, Garcia JG, Brindley DN.(2001) Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovasc Res.;49(3):588-99. Review. 41 Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB.(2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res.;9(15):5721-8. 42 Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M.(2004) Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. ; 101 (6):1364-74. 43 Hsieh CY, Chen CA, Chou CH, Lai KP, Jeng YM, Kuo ML, Wei LH.(2004) Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. J Biomed Sci.;11(2):249-59. 44 Hahn A, Barth H, Kress M, Mertens PR, Goppelt-Struebe M.(2002) Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression. Biochem J.;362(Pt 1):33-40. 45 Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS.(2005) Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res.;65(6):2234-42. 46 Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML.(2004) Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res.;64(2):554-64. 47 Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM.(1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol.;116(3):1973-8. 48 Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM.(1994) YC-1, a novel activator of platelet guanylate cyclase. Blood.;84(12):4226-33. 49 Gupta GP, Massague J. (2004)Platelets and metastasis revisited: a novel fatty link. J Clin Invest.;114(12):1691-3. Review. 50 Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O.(2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. ; 114(12):1714-25. Chapter3 References 1. Schiller CL, Nickolov AG, Kaul KL, Hahn EA, Hy JM, Escobar MT, Watkin WG, Sturgis CD. High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization. Am J Clin Pathol. 2004; 121 (4):537-45. 2. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22 (10):1517-27. 3. Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene. 2004; 23(17):2988-95. 4. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998; 280(8):719-23. 5. Westermann, A.M., Havik, E., Postma, F.R., Beijnen, J.H., Dalesio, O., Moolenaar, W.H. and Rodenhuis, S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998; 9, 437-42. 6. Pages, C., Simon, M.F., Valet, P. and Saulnier-Blache, J.S. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat, 2001; 64, 1-10. 7. Shen, Z., Belinson, J., Morton, R.E. and Xu, Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol, 1998; 71, 364-8. 8. Hu, Y.L., Albanese, C., Pestell, R.G. and Jaffe, R.B. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst, 2003; 95, 733-40. 9. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, An S.G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A. 2005; 102(17):6027-32. 10. Frankel, A. and Mills, G.B. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res, 1996; 2, 1307-13. 11. Hu, Y.L., Tee, M.K., Goetzl, E.J., Auersperg, N., Mills, G.B., Ferrara, N. and Jaffe, R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst, 2001; 93, 762-8. 12. Fishman, D.A., Liu, Y., Ellerbroek, S.M. and Stack, M.S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res, 2001; 61, 3194-9. 13. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y.Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol. 1998;71(3):364-8. 14. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM.Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258(5089):1798-801. 15. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ, Elner SG.Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 1992;141(6):1279-84. 16. Sparmann A, Bar-Sagi D.Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6(5):447-58. 17. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest. 1998; 16(3):152-9. 18. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T.Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers.Cancer Res. 2000; 60(10):2632-5. 19. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL, Hsieh CY.The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 2001; 20(41):5799-809. 20. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998; 94(3):353-62. 21. Kingsbury MA, Rehen SK, Ye X, Chun J. Genetics and cell biology of lysophosphatidic acid receptor-mediated signaling during cortical neurogenesis. J Cell Biochem. 2004; 92(5):1004-12. Review. 22. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, Aoki J, Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature. 2005; 435(7038):104-8. 23. Furui, T., LaPushin, R., Mao, M., Khan, H., Watt, S.R., Watt, M.A., Lu, Y., Fang, X., Tsutsui, S., Siddik, Z.H., Bast, R.C. and Mills, G.B. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res, 1999; 5, 4308-18. 24. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, An S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A. 2005;102(17):6027-32. 25. Goetzl, E.J., Dolezalova, H., Kong, Y., Hu, Y.L., Jaffe, R.B., Kalli, K.R. and Conover, C.A. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res, 1999; 59, 5370-5. 26. Fang, X., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R.B., Wiener, J.R., Erickson, J.R. and Mills, G.B. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci, 2000; 905, 188-208. 27. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, Hsieh CY. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis. 2005; 26(1):45-52. 28. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004; 279(10):9653-61. 29. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J. 1995; 309 ( Pt 3):933-40. 30. Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, Ella KM, Meier KE. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol. 1998; 174(2):261-72. 31. Postma FR, Jalink K, Hengeveld T, Bot AG, Alblas J, de Jonge HR, Moolenaar WH. Serum-induced membrane depolarization in quiescent fibroblasts: activation of a chloride conductance through the G protein-coupled LPA receptor. EMBO J. 1996; 15(1):63-72. 32. Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.J Biol Chem. 2005; 280(10):9498-508. 33. Meng Y, Kang S, Fishman DA. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS Lett. 2005; 579(5):1311-9. 34. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology. 2002; 123(1):206-16. 35. Ye X, Ishii I, Kingsbury MA, Chun J. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta. 2002; 1585(2-3):108-13. Review. 36. Qian, L., Xu, Y., Hasegawa, Y., Aoki, J., Mills, G.B. and Prestwich, G.D. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem, 2003; 46, 5575-8. 37. Dubost JJ, Rolhion C, Tchirkov A, Bertrand S, Chassagne J, Dosgilbert A, Verrelle P. Interleukin-6-producing cells in a human glioblastoma cell line are not affected by ionizing radiation. J Neurooncol. 2002; 56(1):29-34. 38. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer. 2004; 108(6):912-21. 39. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res. 2001; 21(4A):2449-56. 40. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest. 1998; 16(3):152-9. 41. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000; 60(10):2632-5. 42. Allam M, Feely C, Millan D, Nevin J, Davis J, Siddiqui N. Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. Gynecol Oncol. 2004; 93(3):637-41. 43. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. Lysophospholipids Enhance Matrix Metalloproteinase-2 Expression in Human Endothelial Cells. Endocrinology. 2005 May 5; [Epub ahead of print] 44. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001; 61(7):3194-9. 45. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002; 158(2):227-33. 46. Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36176 | - |
dc.description.abstract | Lysophosphatidic acid (LPA)是人體內結構最簡單的磷脂質,在人體中會表現LPA的細胞包含活化的血小板、脂肪細胞、血管內皮細胞,事實上正常微量的LPA對人體內的血管具保護作用、與神經痛覺傳導、胚胎著床、免疫發炎反、傷口癒合應均有關聯。而上述生理作用中的LPA來源主要為活化的血小板,也因此心血管疾病也被研究發現有LPA的異常表現情況。此外,在基礎的研究上則發現卵巢癌細胞與子宮頸癌細胞在受到刺激或平時都會產生並釋放LPA。
LPA在人類腫瘤的角色探索起源於對卵巢癌病人腹水中的growth factors 及cytokines,LPA具有引發卵巢癌細胞胞內鈣離子濃度變化的特性。LPA在婦科癌症(卵巢癌、子宮頸癌、子宮內膜癌)病人血清中會顯著上升,被認為具有發展為診斷標記的潛力。也由此使LPA在卵巢癌中的角色逐漸被研究探討,目前為止卵巢癌是所有人類癌症被認為與LPA最具關聯性的類型,而其在卵巢癌的作用機轉及生物效應也被研究得最為深入。進年來,LPA在其他人類腫瘤如乳癌、大腸癌、子宮頸癌、前列腺癌的研究也日漸受到重視,被認為是癌症治療極佳的分子標地之一。 臨床的研究發現LPA在卵巢癌病人的腹水及其他婦科腫瘤病人血清中的濃度是有意義升高的,其專一性受體LPA1/Edg2, LPA2/Edg4 及 LPA3/Edg7的表現模式在正常細胞與腫瘤細胞有很顯著的差別;正常細胞被發現僅表現LPA1/Edg2。而腫瘤細胞則具有LPA2/Edg4 and LPA3/Edg7的表現。LPA主要會透過其專一性的受體LPA1/Edg2, LPA2/Edg4 及 LPA3/Edg7與G-protein- coupled receptors經由不同的訊息傳遞路徑,調控癌細胞的增生、抗凋亡、轉移侵襲能力、血管新生能力以及抗藥性等生理功能。治療性的基礎研究也發現調控LPA的代謝、專一性的受體的表現或阻斷其訊息傳遞路徑都對卵巢癌治療有很好的效果。 本論文分為三個部分。第一部分,主要探討LPA在卵巢癌細胞調控IL-6表現的機轉,我們的研究結果顯示LPA會藉由PTX敏感性G型蛋白質受體活化PI3K/Akt/NF-kB的訊息傳遞途徑增強卵巢癌細胞表現IL-6。我們的研究結果顯示LPA能透過Gi/PI3K/NFkB的訊息傳遞途徑增強或誘發卵巢癌細胞表現IL-6,此一結果為卵巢癌病人血清或腹水中IL-6的高表現量提出一個來源的解釋。第二部分,主要探討抗血小板活化藥物YC-1應用於LPA活化之細胞生物效應的可行性。本研究中我們以LPA會誘發細胞內鈣離子濃度變化的特性,測試能抑制細胞內鈣離子濃度變化的藥物 YC-1對於LPA誘發作用的影響。結果顯示YC-1能透過抑制LPA誘發的β-integrin的表現而影響卵巢癌細胞附著,另一方面YC-1也能抑制LPA對懸浮狀態巢癌細胞的抗凋亡作用以及能抑制血管內皮細胞的VEGFR2的活化而影響LPA調節之促血管新生作用。此一結果顯示YC-1應用於LPA活化之細胞生物效應的可行性。第三部分,主要探討LPA在子宮頸癌細胞的生物效應。我們的研究結果顯示LPA對於子宮頸癌細胞具有促血管新生、促細胞移行侵襲及增加對放射線治療的抗性等作用。我們也發現LPA在子宮頸癌細胞的促血管新生效應與對放射線治療的抗性等效應,分別與LPA會誘發子宮頸癌細胞產生IL-8及IL-6有關。此部分之結果在現有文獻中尚未有類似結果發表。 綜合我們的研究結果與國際上的相關文獻的知識,我們認為作用於LPA專一性的受體或作用於LPA活化之訊息傳遞路徑或調控LPA的代謝等方式將是以LPA為分子治療標的的發展方向。此外我們也期望藉由本研究結果闡明LPA在婦癌細胞惡性化過程中可能具有的生物效應與作用機轉進而尋求可能的治療方式,以釐清將LPA作為婦癌分子治療標的可行性。 | zh_TW |
dc.description.abstract | Bioactive lysophospholipid, lysophosphatidic acid (LPA), is consistently raised in the ascites of patients with ovarian cancer and cervical cancer. In this study, we elucidate the role of LPA in the pathogenesis of ovarian cancer and cervical cancer.
In the first chapter, we investigated how LPA affects IL-6 production in ovarian cancer cells. Experimental results indicated that LPA stimulates IL-6 expression in all ovarian cancer cell lines tested, but not in normal ovarian surface epithelial (NOSE) cells, owing to the lack of LPA specific Edg4 and/or Edg7 receptors in NOSE cells. This work demonstrated that LPA transcriptionally activates IL-6 expression, which can be totally blocked by pertussis toxin, indicating that Gi-mediated signaling is critically involved in inducing IL-6 by LPA. Pharmacological and genetic inhibition assays revealed that Gi-mediated PI3K activation phosphorylated downstream Akt and subsequently induced NF-kB activation causes the induction of IL-6 by LPA in SK-OV-3 cells. In sum, dada presented here demonstrate that LPA is an important inducer of IL-6 and LPA regulated IL-6 expression via a Gi/ PI3K-Akt/ NF-kB pathway in ovarian cancer cells. In the second chapter, we investigated the biological effect on the clear cell type of ovarian cancer cell line ES-2, furthermore, we used ES-2 clear cells for testing the therapeutic effect of YC-1(3-(53-Hydroxymethyl- 23furyl)-1-benzyl indazole) which is a Ca(2+) influx inhibitor on the LPA mediated biological effects in vitro and in vivo. Our results indicated that LPA specific Edg receptors 2, 4 and 7 were all expressed in ES-2 cells with different level. LPA could not only enhance ES-2 cells adhesion to type I collagen but also enhance the VEGF and IL-6 expression. LPA could inhibit LPA enhanced cell adhesion through down regulated LPA induced ß1-integrin, and the rescue effect of LPA on ES-2 cells anoikis. We further tested the therapeutic effect of YC-1 on ES-2 tumorigenesis in nude mice, the data indicated that i.p. administration significant attenuated the ascites formation, and sustain the survival days in nude mice. And we found that YC-1 can not reduce the LPA enhanced VEGF expression in the ES-2 cells condition medium, but YC-1 could inhibit the condition medium modulated HUVECs monolayer permeability, HUVECs tube formation on matrigel and angiogenesis on chicken embryo chorioallantoic membrane assays (CAM), and the mechanism may due to YC-1 downregulated VEGF or condition medium caused VEGF receptor 2(KDR) phosphorylation. In the third chapter, we investigate the biological role of LPA in cervical cancer, we found that the LPA specific receptors, including Edg2, Egd4 and Edg7, were differentially expressed in cervical cancer cell lines. Physiological achievement level of LPA treatment shows survival promoting effects in cervical cancer cell lines under the serum-starved condition. LPA also stimulated significant elevation of IL-6 and IL-8 in cervical cancer HeLa and SiHa cells. By using neutralizing antibodies to block LPA induced IL-6 and IL-8 in the condition medium, we found that LPA induced IL-8 modulated the tube formation, proliferation and permeability on HUVECs, and also the angiogenesis in the chorioallantoic membrane (CAM) assay system. By using IL-6 neutrolizing antibodies to block IL-6, we found that the rescue effect of LPA on radiation-reduced colony formation was alleviated. Further more, LPA treatment also enhanced the cell migration in wound-healing assay, invasiveness in Matrigel coated Boyden chamber assay, and in the in vivo invasiveness/ intravasation capability assay in chicken embryo. In sum, our study indicated that LPA is a multiple function activating factor in the human cervical carcinoma as well as in ovarian cancer, LPA may provide a new targeting treatment of cervical cancer and ovarian cancer. Furthermore, anti-platelet drug, YC-1, may be a potent drug for molecular targeting on LPA mediated tumorigenesis and angiogenesis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T07:53:03Z (GMT). No. of bitstreams: 1 ntu-94-D89447004-1.pdf: 1041331 bytes, checksum: ab9276bb0da90e45d0d543f1dfff40c2 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | Acknowledgement--------------------------3
Chinese abstract-------------------------4 Englis abstract--------------------------6 Chapter 1 Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/ PI3K-Akt / NF-kB pathway by lysophosphatidic acid, an ovarian cancer activating factor------------------------------------------8 Introduction-----------------------------9 Materials and Methods-------------------11 Results---------------------------------14 Discussion------------------------------23 References------------------------------25 Chapter 2 YC-1 inhibit lysophosphatidic acid enhanced ovarian cancer ES-2 cells adhesion and tumorigenesis and angiogenesis in vivo------------------------------------30 Introduction----------------------------31 Materials and Methods-------------------33 Results---------------------------------37 Discussion------------------------------47 References------------------------------49 Chapter 3 Lysophosphaditic acid enhances angiogenesis, invasiveness, and radioresistance in human cervical carcinoma-------------------------------54 Introduction----------------------------55 Materials and Methods-------------------56 Results---------------------------------60 Discussion------------------------------74 References------------------------------76 Publication list------------------------81 | |
dc.language.iso | en | |
dc.title | 水解磷脂酸對人類子宮頸癌細胞及卵巢癌細胞的生物效應探討 | zh_TW |
dc.title | The biological effects of lysophosphatidic acid (LPA) in Human cervical cancer and ovarian cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 謝長堯 | |
dc.contributor.oralexamcommittee | 賴明坤,王朝鐘,翁一鳴 | |
dc.subject.keyword | 水解磷脂酸,子宮頸癌,卵巢癌, | zh_TW |
dc.subject.keyword | LPA,cervical cancer,ovarian cancer, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-07-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 1.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。